Verinurad
- Generic Name
- Verinurad
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H16N2O2S
- CAS Number
- 1352792-74-5
- Unique Ingredient Identifier
- 12WJ62D047
- Background
Verinurad has been used in trials studying the basic science and treatment of Gout, Gout and Hyperuricemia, and Gout and Asymptomatic Hyperuricemia.
- Associated Conditions
- -
- Associated Therapies
- -
Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT04532918
- Locations
- π©πͺ
Research Site, Berlin, Germany
Study of Verinurad in Heart Failure With Preserved Ejection Fraction
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 159
- Registration Number
- NCT04327024
- Locations
- πΈπ°
Research Site, Svidnik, Slovakia
A Study to Assess the Effect of Verinurad on the Electric Activity of the Heart
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2022-01-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT04256629
- Locations
- π©πͺ
Research Site, Berlin, Germany
A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 861
- Registration Number
- NCT03990363
- Locations
- πͺπΈ
Research Site, Valencia, Spain
A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT03836599
- Locations
- πΊπΈ
Research Site, Glendale, California, United States
A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT03316131
- Locations
- πΊπΈ
Research Site, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2024. All Rights Reserved by MedPath